RLMD
RLMD clinical trials: RELMADA THERAPEUTICS, INC.
Every trial on ClinicalTrials.gov where RELMADA THERAPEUTICS, INC. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 11
- Trials linked
- 11
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
RLMD on the catalyst calendar · RLMD registry changes
- Primary completion Dec 2029Sponsor estimatePhase 3NCT07464145A Study of NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-muscle Invasive Bladder CancerRelmada Therapeutics, Inc. · Bladder (Urothelial, Transitional Cell) CancerNot yet recruitingRLMDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2027Sponsor estimatePhase 2NCT06663137A Study to Evaluate the Safety and Efficacy of NDV-01 in Participants With NMIBCRelmada Therapeutics, Inc. · Non Muscle Invasive Bladder CancerRecruitingRLMDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredNo phase registeredNCT06009003Individual Patient Esmethadone (REL-1017) Expanded Access ProgramRelmada Therapeutics, Inc. · Major Depressive DisorderNo longer availableRLMDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 30, 2027Sponsor estimatePhase 3NCT07342517A Study of NDV-01 as an Intravesical Administration to Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)...Relmada Therapeutics, Inc. · Bladder (Urothelial, Transitional Cell) CancerWithdrawnRLMDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 1, 2029Sponsor estimatePhase 3NCT07313891A Study of Adjuvant NDV-01 (Sustained-release Gemcitabine-docetaxel) for the Treatment of Intermediate Risk NMIBC Following TURBTRelmada Therapeutics, Inc. · Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)WithdrawnRLMDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 27, 2023ActualPhase 3NCT04855760Safety of REL-1017 for Major Depressive DisorderRelmada Therapeutics, Inc. · Major Depressive DisorderCompletedRLMDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 1, 2022ActualPhase 3NCT04688164A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)Relmada Therapeutics, Inc. · Major Depressive DisorderCompletedRLMDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 13, 2022ActualPhase 3NCT05081167A Study to Assess the Efficacy and Safety of REL-1017 as Monotherapy for Major Depressive Disorder (MDD)Relmada Therapeutics, Inc. · Major Depressive DisorderCompletedRLMDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 30, 2019ActualPhase 2NCT03051256Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDDRelmada Therapeutics, Inc. · Depressive Disorder, MajorCompletedRLMDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2, 2015ActualPhase 1NCT03637361Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of REL-1017 (d-Methadone)Relmada Therapeutics, Inc. · Neuropathic PainCompletedRLMDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 16, 2015ActualPhase 1NCT03638869Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of REL-1017 (d-Methadone)Relmada Therapeutics, Inc. · Neuropathic PainCompletedRLMDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 11 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner